Covid Inquiry: What have we learnt so far?
The first phase of the Covid Inquiry has come to an end. What have we learnt over the past six weeks?
Similar Posts
Moderna Covid vaccine sales plunge by two-thirds in 2023, but meet company’s $6 billion forecast
Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Monday said its Covid vaccine sales plunged by about two-thirds in 2023 to $6.7 billion, as fewer people rolled up their sleeves for an updated version of the jab. The revenue from the shots met Moderna’s forecast for the year, even as sales plummeted from the…
Peanut death inquest told of restaurant’s blank allergy forms
An inquest hears a restaurant linked to a peanut allergy death had incomplete documentation.
FDA Finds ‘Extremely High’ Lead Levels In Cinnamon Used In Tainted Fruit Pouches
The cinnamon, which originated from a plant in Ecuador, had lead levels more than 2,000 times higher than a maximum level proposed by the FDA, officials said.
Here are the big health sector themes to watch next year
An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | Reuters The health-care sector has wiped out much of its losses for the year during the December market rally. Beaten-down biotech and medical device makers have seen the biggest rebound this month, and…
Junior doctors’ strike: The ‘huge effort’ to keep a hospital running
Meanwhile, a matron running a post-surgery recovery ward told me her nurses were having to take on emergency cases during the strike. This, she said, was a “whole different kettle of fish” which required different skills and experience. Her already overstretched staff were worried about doing their best for patients, she said, which was “frustrating”.
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because…
